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The treatment of infections caused by resistant microorganisms represents a big challenge in healthcare 
due to limited treatment options. For this reason, the discovery of new active substances which are able 
to perform innovative and selective actions is of great impact nowadays. Statins and triazenes (TZC) 
have consolidated as a promising class of compounds, characterized by the expressive biological activity, 
especially antimicrobial activities. The aim of this study was to assess the in vitro synergistic antibacterial 
effect of the association of statins and a new TZC complex {[1-(4-bromophenyl)-3-phenyltriazene N3-
oxide-κ2 N1,O4](dimethylbenzylamine-κ2 C1,N4)palladium(II)} (Pd(DMBA)LBr) against American Type 
Culture Collection (ATCC) strains and clinical isolates. The complex and the statins showed bacterial 
activity of all tested strains and clinical isolates, evidencing that TZC complexion with metals can be 
promising. Simvastatin showed synergy when associated to the complex (FICI≤0.5), being the minimum 
inhibitory concentration (MIC) of 16 µg mL-1 found in 6 samples. Thus, it is possible to infer that the 
association between Pd(DMBA)LBr and simvastatin consists of an alternative to increase the pontential 
of these compounds, since statins have low toxicity. 
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INTRODUCTION
Antimicrobial resistance is a serious public health 
issue worldwide. Multi-drug resistant microorganisms 
(MDR) are an increasing concern since they show low 
susceptibility to different classes of antimicrobials that are 
commonly prescribed in hospitals (WHO, 2014; Tzialla et 
al., 2015). It has also become a challenge for healthcare 
professionals because therapy options for the treatment 
of some infections caused by MDR are more and more 
restrict due to the fast emergence and dissemination of 
these microorganisms (Azevedo, Silva, 2012; Thangamani 
et al., 2015; Karam et al., 2016).
This resistance occurs due to several reasons, mainly 
the indiscriminate use of these agents, thus decreasing 
the amount of drugs available for the treatment of such 
infections (Azevedo, Silva, 2012; Karam et al., 2016). 
Therefore, there is the urge to discover new drugs with 
antibacterial properties, in addition to associations in the 
search of synergistic effects (Kalaivani, 2012; Thangamani 
et al., 2015; Tizotti et al., 2016).
Statins are a class of drugs which have shown a 
promising antibacterial activity against several bacterial 
species, being used for the reduction of lipids in patients 
with high cholesterol levels as well as showing anti-
inflammatory activity (Almog et al., 2004; Lopez-
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Cortes et al., 2013; Kozarov, Padro, Badimon, 2014; 
Thangamani et al., 2015). Also, other substances worth 
noticing are triazenes (TZC), which contain an aliphatic 
chain composed by three nitrogen atoms interconnected 
in sequence (N=N-N), responsible for their biological 
properties (Moore, Robinson, 1986). These substances 
show wide pharmacological versatility such as antifungal, 
antileukemia and antibacterial activity, making them the 
focus of several studies (Hörner et al., 2008; Domingues 
et al., 2010; Mohammadi, 2014; Tizotti et al., 2016). 
Also, in order to increase the biological activity and 
stability of TZC in medicines, there is a growing interest 
in associating these compounds with metals (Sreedhara, 
Cowan, 2001; Karami et al., 2017). Compounds that 
contain palladium (Pd(II)) are worth highlighting, mainly 
regarding antitumor activity, since they have more stability 
and less toxicity when compared to platin-based anticancer 
compounds, due to their similar structural behaviour 
(Dupont, Consorti, Spencer, 2005; Massai et al., 2016; 
Karami et al., 2017). Also, their potential antibacterial 
activity can have their action significantly increased up to 
16 times when associated to antimicrobials than the free 
drug (Guerra et al., 2005).
The aim of this study was to assess the in vitro 
synergistic antibacterial effect of the association between 
statins and a new TZC complex {[1-(4-bromophenyl)-3-
phenyltriazene N3-oxide-κ2 N1,O4](dimethylbenzylamine-κ2 
C1,N4)palladium(II)} (Pd(DMBA)LBr), their ligands 
N,N’-dimethylbenzylamine (DMBA), 1-Phenyl-3-
(4-bromophenyl)triazene N1-hydroxide (HLBr), and 
precursor ([Pd(DMBA)(µ-Cl)]2) against American Type 
Culture Collection (ATCC) strains and clinical isolates. 
MATERIAL AND METHODS
Chemical compounds 
The TZC were previously synthesized and chemically 
characterized in the Núcleo de Investigação de Triazenos 
e Complexos (NiTriCo) of Universidade Federal de Santa 
Maria (UFSM). Statins were purchased commercially in 
the form of their active principle (atorvastatin, formula: 
C66H68CaF2N4O10.3H2O, PM = 1209.4; simvastatin, 
formula: C25H38O5, PM = 418.57).
Experimental
The synthesis of the ligand HLBr was realized 
according the literature and based on Scheme 1, while 
the synthesis of the complex Pd(DMBA)LBr from the 
ligand HLBr and the precursor complex [Pd(DMBA)Cl]2 
followed according Scheme 2 (Martins et al., 2017). 
Synthesis of {[1-(4-bromophenyl)-3-
phenyltriazene N3-oxide-κ2 N1,O4](dimethyl-
benzylamine-κ2 C1,N4)palladium(II)}  
(Pd(DMBA)LBr)
To obtain the complex Pd(DMBA)LBr a solution 
of the protonated ligand HLBr (0.05 g; 17.12 mmol) in 
20 mL of tetrahydrofuran was prepared. To this transparent 
pale-yellow solution five drops of a concentrate solution of 
KOH in methanol were added under continuous stirring at 
room temperature. The reaction mixture changes to intense 
yellow indicating the presence of the deprotonated free 
SCHEME 1 - Reaction scheme of the synthesis of the ligand HLBr. 
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ligand anion [LBr]-. A solution of the precursor complex 
[Pd(DMBA)(µ-Cl)]2 (0.053 g; 0.097 mmol) dissolved 
in 10 mL of tetrahydrofuran was added under stirring at 
room temperature - [Pd(DMBA)(µ-Cl)]2 was previously 
prepared according Cope and Friedrich (1968). The 
reaction mixture was stirred 1 h while the color changes 
to opaque yellow. The reaction mixture was filtered. After 
evaporation of the solvent mixture at room temperature, 
transparent yellow crystals with lozenge shape were 
obtained. Yield: 50% (0.049 g) based on 1-Phenyl-3-
(4-bromophenyl)triazene N1-hydroxide. Anal. Calc. for 
C21H21BrN4OPd: C, 47.43; H, 3.98; N,10.54; Found: C, 
45.9; H, 3.93; N,10.19. IR nmax/cm-1, KBr pellet: 3040 - 
2833 (νC-H); 1588 (νC=C); 1480 (δN-H); 1417 (νN=N); 
1314 (N-N-N); 1278 (νN→O); 665 (Car-Br); 1163 (N-N). 
NMR 1H (600 MHz DMF-d7) δ =7.94 ppm (d, J = 8.54 Hz, 
2H, ArH); δ=7.53-7.33 ppm (m, 7H, ArH); δ =7.00 ppm 
(d, J =7,27 Hz, 1H, ArH); δ =6.88 ppm (t, J =7,27 Hz, 
1H, ArH); δ=6.61 ppm (t, J = 7.42 Hz, 1H, ArH); δ =6.31 
ppm (d, J = 7.66 Hz, 1H, ArH); δ =4.09 ppm (s, J = 19.34 
Hz , 2H, CH2); δ =3.49 ppm (s, CH3, 6H). NMR 13C (600 
MHz DMF-d7) δ =149.07 ppm (C18); δ =148.91 ppm (C1); 
δ =148.44 ppm (C13); δ =141.19 ppm (C7); δ =134.42 ppm 
(C14); δ =131.42 ppm (C3, C5); δ =129.22 ppm (C9,C11); 
δ =127.40 ppm (C10); δ =126.62 ppm (C2,C6); δ =124.37 
ppm (C15); δ =123.57 ppm (C16); δ =121.76 ppm (C17); 
δ =118.61 ppm (C8,C12); δ =117.42 ppm (C4); δ =72.39 
ppm (C19); δ =51.69 ppm (C21, C22).
In vitro antibacterial activity
The in vitro antibacterial activity was evaluated 
against different strains ATCC, including Bacillus cereus 
ATCC 14579, Enterobacter hormaechei ATCC 700323, 
Enterococcus casseliflavus ATCC 700327, Enterococcus 
faecalis ATCC 29212, Enterococcus faecalis ATCC 
51299, Escherichia coli ATCC 25922, Escherichia 
coli  ATCC 35218, Klebsiella pneumoniae  ATCC 
700603, Micrococcus luteus ATCC 7468, Pseudomonas 
aeruginosa ATCC 27853, Salmonella typhimurium ATCC 
14028, Salmonella spp. ATCC 52117, Staphylococcus 
aureus ATCC 25923, Staphylococcus aureus ATCC 
29213, Staphylococcus aureus BAA 1026, Staphylococcus 
aureus BAA 976, Staphylococcus aureus BAA 977, 
Staphylococcus epidermidis ATCC 12228 and against 
ten coagulase-negative staphylococci isolates in newborn 
blood cultures in 2014. Clinical isolates were identified 
through by automated system Vitek® 2 (bioMérieux, 
France).
Determination of the Minimum Inhibitory 
Concentration (Mic)
Bacterial isolates and ATCC strains, stored in 
15% glycerol at -80 °C, were pre-activated using the 
agar trypticase soy medium (TSA) for 24 h at 35 ± 2 °C. 
Evaluation of the antibacterial activity of the compounds 
was performed using the conventional method of broth 
microdilution for Minimum Inhibitory Concentration 
(MIC) based on the Clinical and Laboratory Standards 
Institute guidelines (CLSI, 2012a). The test compounds 
was diluted in ethanol at a concentration of 20.480 µg 
mL-1 and then successive dilutions were made with 
concentrations from 1.024 to 1 µg mL-1, with ethanol 
concentration 5% to 0.0048%. The bacterial inoculum 
was prepared using a 0.5 McFarland scale, so that each 
well contained 5 x 105 CFU mL-1. Plates were incubated 
for 24 h at 35 ± 2 °C and after this period, the MIC 
SCHEME 2 - Reaction scheme of the synthesis of the complex Pd(DMBA)LBr from the ligand HLBr and the complex [Pd(DMBA)
Cl]2 as precursors. 
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was determined visually as the lowest concentration 
that completely inhibited growth of microorganisms in 
dilution wells. For control and comparison MIC was 
determined as a broad spectrum antibacterial drug used in 
therapeutics: Tigecycline (Tygacil® - Wyeth). The drug 
was dissolved in physiological solution in the same manner 
as the compounds, but at a lower concentration (5.120 
µg mL-1). After successive dilutions were performed at 
concentrations of 256 to 0.25 µg mL-1. Tests were also 
conducted using only ethanol to demonstrate that it did 
not interfere with the activity. 
Statistical analysis 
The analysis of the combination of TZC and statins 
was obtained by calculating the Fractional Inhibitory 
Concentration Index (FICI). The FICI was interpreted 
as “synergic” (FIC≤0.5); “no interaction” (FIC>0.5 and 
≤4.0) and “antagonism” (FIC>4.0) (Odds, 2003; Konaté 
et al., 2012).
Ethical considerations 
This study was approved by the Research Ethics 
Committee (CEP) of UFSM, under the certificate 
number of presentation for ethical consideration (CAAE) 
38850614.4.0000.5346.
RESULTS
All compounds showed antibacterial activity against 
the strains tested. The MIC of ATCC strains against 
ligands, precursor and complex, associated or not to 
statins, free palladium(II), tigecycline and fici values, are 
shown in Table I; and it is possible to observe the same 
parameters in Table II, however against the 10 clinical 
isolates. Simvastatin showed an activity similar or better 
than atorvastatin in all ATCC strains and clinical isolates 
analyzed, with the lowest MIC (=16 μg mL-1) found in the 
ATCC strain of S. aureus BAA 976. Also, S. aureus BAA 
977, Micrococcus luteus 7468 and the isolates 8 showed 
MIC=32 μg mL-1. It has also been possible to observe that 
the best activity occurred in Gram-positive bacteria.
Regarding TZC, the DMBA ligand and the precursor 
([Pd(DMBA)(µ-Cl)]2) showed MIC≥128 μg mL-1 for all 
the microorganisms analyzed. The ligand HLBr showed 
good activity in ATCC strains, with MIC=64 μg mL-1 for E. 
faecalis ATCC 51299 and S. aureus ATCC 25923, and for 
the clinical isolates the lowest MIC was 128 μg mL-1. As 
for the palladium(II) complex, (Pd(DMBA)LBr) showed 
greater antibacterial potential in nearly all microorganisms 
when compared to the ligand and the precursor, resulting 
in MIC=64 μg mL-1 for some clinical isolates and MIC=32 
μg mL-1 for the ATCC strain of E. faecalis 51299.
When TZC was associated with simvastatin, it was 
possible to observe a decrease of MIC values in both 
ATCC strains and clinical isolates. The DMBA associated 
with simvastatin showed synergy (FICI≤0.5) against 
strains of B. cereus ATCC 14579, E. faecalis ATCC 51299, 
S. aureus ATCC 25923, S. aureus 29213, and S. aureus 
BAA 1026. The precursor ([Pd(DMBA)(µ-Cl)]2) showed 
synergy against these strains as well as Salmonella ATCC 
52117 and isolate 2. 
The ligand 2 (HLBr), when associated to simvastatin, 
showed MIC=64 µg mL-1 for Salmonella ATCC 52117; 
MIC=32 μg mL-1 for B. cereus, S. aureus 2923, S. aureus 
BAA 1026, isolates 4 and 6; MIC=16 μg mL-1 for E. 
faecalis ATCC 51299 and S. aureus 25923, with FICI<0.5 
against these samples. The complex (Pd(DMBA)LBr) 
was twice more active than its free ligands and precursor 
when associated with simvastatin, showing synergy 
against the strains E. casseliflavus ATCC 700327, E. coli 
ATCC 25922, P. aeruginosa ATCC 27853 and S. aureus 
29213, S. aureus BAA 1026, isolates 1, 2, 3, 4, 5, 6 and 
7, with FICI≤0.5. As for the association of TZC with 
atorvastatin, no synergy was evidenced, but MIC values 
were similar to the ones obtained when the compounds 
were separately tested, except for a few strains. 
DISCUSSION
The emergence of antimicrobial resitance shows the 
need for searching new drugs, as well as their association 
(Masadeh et al., 2012). Some studies have evidenced 
a possible antibacterial effect of this class of drugs, 
associated to antimicrobials or not in order to reduce 
morbidity and mortality of several infectious diseases 
(Masadeh et al., 2012; Ajrouche et al., 2013; López-Cortés 
et al., 2013; Kozarov, Padro, Badimon, 2014; Graziano et 
al., 2015; Thangamani et al., 2015).
In this study, it was possible to observe that statins 
are able to induce variable degrees of antibacterial 
activity, with simvastatin being more potent than 
atorvastatin. A study developed in 2012 comparing 
the antibacterial activity of atorvastatin, simvastatin 
and rosuvastatin showed that the two first statins were 
the most potent in Gram-positive microorganisms, 
with MIC=166.67±72.16 μg mL-1 for atorvastatin and 
MIC=104.17±36.08 μg mL -1 for simvastatin in E. 
faecalis 51299 strains, a result similar to the one found 
in our study. However, below-average results were 
found for E. coli 35218 (MIC=26.04±9.02 μg mL-1 and 
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MIC=58.08±18.04 μg mL-1), and S. epidermidis 12228 
(MIC=26.04±9.02 μg mL-1), respectively (Masadeh et 
al., 2012). 
Graziano et al. has detected that simvastatin was 
the only statin with antibacterial activity against clinical 
isolates and ATCC strains of S. aureus susceptible (MSSA) 
and resitant to methycillin (MRSA), with S. aureus 29213 
showing MIC=15.65 μg mL-1 (Graziano et al., 2015). The 
difference of MIC between these studies can be attributed 
to the different design of the study performed (Ting, 
Whitaker, Albandar, 2016). We suppose that it could 
have been due to the different methodology used in the 
solubility of statins, since the active principles used in our 
study were dilluted in ethanol, whereas other researchers 
used dimethyl sulphoxide (DMSO). Thus, we performed 
the MIC of these strains by using the same methodology 
used in other studies, and results remained the same as 
when principles were dilluted in ethanol. However, it is 
known that according to the document M100-S22 from 
CLSI, DMSO can inactivate DNA of microorganisms 
when used in doses higher than 1%, interfering with the 
antibacterial activity (CLSI, 2012b).
All statins induce their antihyperlipidemic activity 
through the same mechanism of action in eukaryotic cells, 
completely inhibiting the Class I 3-hydroxi-3-methyl-
glutaryl-coenzyme to reductase (HMG-CoA), hindering 
the formation of mevalonate of HMG-CoA, and leading to 
a decrease in biosynthesis of cholesterol and an increase in 
the removal of circulation of low density lipoproteins (LDL) 
(Shitara, Sugiyama, 2006; Masadeh et al., 2012; Graziano et 
al., 2015). However, studies have shown that it is unlikely 
that the antibacterial activity shown by this class of drugs 
is related to this action mechanism, since mechanisms of 
antimicrobial effects of statins are yet to be elucidated 
(Masadeh et al., 2012; Ting, Whitaker, Albandar, 2016). A 
possible mechanism which can be related would be due to 
promoting apoptosis in microbial cells or the hydrofobic 
nature of statins, leading to the rupture of the bacterial 
membrane, resulting in cell death (Bergman et al., 2011; 
Tapia-Perez et al., 2011; Masadeh et al., 2012).
Other researchers have revealed that simvastatin 
inhibits the multiple biosynthetic pathways and the cellular 
processes in bacteria, including the selective interference 
of bacterial proteic synthesis, aiding the ability of this drug 
to suppress the production of some bacterial toxins such as 
α-hemolysin and Panton-Valentine leucocidin (Thangamani 
et al., 2015). Furthermore, Thangamani et al. (2015) have 
shown that simvastatin has an excellent activity against 
biofilm-forming bacteria in Staphylococcus.
In terms of the difference of MIC in statins, it can 
be due to the difference in their chemical structure as well 
as their production. Simvastatin is the semisynthetic form 
which derives from lovastatin, a product of Penicillium 
citrinum, with higher intrinsic antibacterial activity. 
Atorvastatin, on the other hand, is the pure synthetic 
form (Mason et al., 2005; Jerwood, Cohen, 2008; Ting, 
TABLE II - Minimum Inhibitory Concentrations (MIC) of ligands, precursor and complex, associated or not with statins against CoNS
Micro-
organism
µg mL-1
A S L1 L1+ A FICI L1+S FICI L2 L2+A FICI L2+S FICI P P+A FICI P+S FICI C C+A FICI C+S FICI
Pd 
livre
Isolate 1 256 128 512 256 1.5 64 0.6 256 256 2 64 0.8 256 256 2 64 0.8 128 128 1.5 32 0.5 256
Isolate 2 256 128 256 256 2 64 0.8 128 128 1.5 64 1 256 128 1 32 0.4 64 64 1.25 16 0.4 256
Isolate 3 256 128 256 256 2 64 0.8 128 128 1.5 64 1 256 128 1 64 0.8 64 64 1.25 16 0.4 256
Isolate 4 256 128 256 128 1 128 1.5 256 128 1 32 0.4 256 128 1 128 1.5 128 128 1.5 32 0.5 256
Isolate 5 128 64 128 128 2 64 1.5 128 128 2 32 0.8 128 128 2 64 1.5 64 64 1.5 16 0.5 256
Isolate 6 256 128 256 256 2 128 1.5 128 128 1.5 32 0.5 128 128 1.5 128 2 64 64 1.25 16 0.4 256
Isolate 7 128 64 256 256 3 32 0.6 128 128 2 32 0.8 256 128 1.5 64 1.3 64 64 1.5 16 0.5 256
Isolate 8 128 32 128 128 2 32 1.3 128 128 2 64 2.5 128 128 2 64 2.5 64 64 1.5 16 0.8 256
Isolate 9 256 128 512 256 1.5 64 0.6 128 128 1.5 64 1 256 128 1 64 0.8 64 64 1.25 32 0.8 256
Isolate 10 128 64 128 128 2 64 1,5 128 128 2 64 1.5 128 128 2 64 1.5 64 64 1.5 32 1 256
MIC50 256 128 256 256 - 64 - 128 128 - 64 - 256 128 - 64 - 64 64 - 16 - 256
MIC90 256 128 512 256 - 128 - 256 128 - 64 - 256 128 - 128 - 128 128 - 32 - 256
A = Atorvastatin; S = Simvastatin; L1= Ligand 1 N,N’-dimethylbenzylamine (DMBA); FICI= Fractional Inhibitory Concentration Index; L2 = Ligand 2 1-Phenyl-
3-(4-bromophenyl)triazene N1-hydroxide (HLBr); P = Precursor [Pd(DMBA)(µ-Cl)]2; C = Complex {[1-(4-bromophenyl)-3-phenyltriazene N3-oxide-κ2 N1, 
O4](dimethylbenzylamine-κ2 C1, N4)palladium(II)} (Pd(DMBA)LBr); Pd = Palladium; Tig = Tigecycline; * = Test not realized. Isolates 1, 10 = Staphylococcus 
hominis; Isolates 2, 3, 4, 5, 7, 9 = Staphylococcus epidermidis; Isolate 6 = Staphylococcus saprophyticus; Isolate 8 = Staphylococcus capitis.
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Whitaker, Albandar, 2016). These two are lipophilic 
statins, thus simvastatin probably goes through the cell 
membrane more easily, causing the inhibition of bacteria, 
depending on the dose. Atorvastatin has not shown 
significant antimicrobial activity, although it is lipophilic, 
and it is justified because this statin is not derived from 
funghi (Mason et al., 2005; Graziano et al., 2015). 
However, more studies regarding statins structure are 
needed in order to ellucidate their effect against bacteria 
(Graziano et al., 2015).
Regarding TZC, several studies using these 
compounds have shown that they have antimicrobial 
activity (Hörner et al., 2008; Domingues et al., 2010; 
Ombaka, Muguna, Gichumbi, 2012; Mohammadi, 2014; 
Paraginski et al., 2014; Tizotti et al., 2016), being proposed 
that their action mechanism occurs due to the chelating 
activity to metallic ions from the bacterial cell wall, 
inhibiting stages of bacterial synthesis, leading to cell 
death (Hörner et al., 2008; Ombaka, Muguna, Gichumbi, 
2012; Yeo et al., 2013). 
The highest antibacterial activity was detected in 
Gram-positive microorganisms, and could be justified 
by the difference in the cell wall structure of these 
bacteria, which is less complex and has a thick layer of 
peptidoglycan. Gram-positive bacteria need this layer for 
their protection and the maintenance of osmotic pressure, 
thus, antibacterial activity may be related to the inhibition 
of the synthesis of the peptidoglycan, leading to cell death 
(Yeo et al., 2013).
The DMBA ligands and the precursor [Pd(DMBA)
(µ-Cl)]2 showed MIC≥128 µg mL-1. TZC complexed with 
palladium(II) showed better activity against the strains 
tested when compared to free ligands and precursor, 
proving to be an alternative for a new class of drugs with 
antibacterial activity. This activity can be justified since 
TZC complexed with transition metals such as Pd(II) can 
interact and cause damage to the DNA, providing a potent 
antibacterial activity, in addition to blocking cancer cells 
division leading to cell death (Hecht, 2000; Song et al., 
2006; Paraginski et al., 2014). Therefore, complementary 
studies must be performed for the assessment of other 
biological parameters, their toxicity and therapeutic 
efficacy (Nunes et al., 2014). 
When associating TZC with atorvastatin or 
simvastatin, simvastatin has shown synergy. It is estimated 
that a third of American adults over 45 years old make 
use of these drugs routinely (Wang et al., 2016). These 
drugs show a good safety profile with limited secondary 
effects, with low toxicity, allowing a frequent use in 
patients with high cholesterol levels (Thangamani et al., 
2015; Ting, Whitaker, Albandar, 2016). Also, studies show 
that patients who make use of this class of drugs have a 
lower risk of acquiring bacterial infections, proving the 
correlation of the use of statins and a lower incidence of 
sepsis and mortality related to these infections (Almog et 
al., 2004; Ajrouche et al., 2013; López-Cortés et al., 2013).
Thus, according to MIC and FICI values obtained, 
we can infer that TZC complexed with palladium(II) 
significantly increases the antibacterial activity, and 
worked even better when associated with simvastatin. The 
documentation of this synergistic effect is of great impact 
for the treatment of MDR bacteria together with the low 
toxicity perfomance of simvastatin. 
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